Skip to main content
$60.45 -1.70 (-2.74%) At close · Jul 24
Market Cap
$9.37B
Shares
154.99M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Frank Laukien $4,706,388
Mark R. Munch $2,178,054
Gerald Herman $2,010,308
Bruker NANO Group $1,422,590
Falko Busse $1,420,798
Fiscal 2024
Executive Total
Frank Laukien $5,527,304
Mark R. Munch $2,642,108
Gerald Herman $2,288,269
Bruker BioSpin Group $1,859,831
Bruker CALID Group $1,522,279
Bruker NANO Group $1,522,279
Falko Busse $1,465,032
Fiscal 2023
Executive Total
Frank Laukien $5,858,761
Mark R. Munch $2,726,522
Gerald Herman $2,204,302
Bruker CALID Group $1,472,236
Bruker NANO Group $1,472,236
Bruker BioSpin Group $1,345,365
Falko Busse $1,345,365
Fiscal 2022
Executive Total
Frank Laukien $5,057,195
Mark R. Munch $2,501,229
Bruker NANO Group $2,501,229
Gerald Herman $1,898,666
Juergen W. Srega $1,280,420
Bruker CALID Group $1,280,420
Bruker BioSpin Group $1,150,440
Falko Busse $1,150,440
Fiscal 2021
Executive Total
Frank Laukien $5,594,539
Mark R. Munch $2,582,565
Bruker NANO Group $2,582,565
Gerald Herman $1,940,547
Bruker CALID Group $1,600,210
Juergen W. Srega $1,600,210
Falko Busse $1,103,967
Bruker BioSpin Group $1,103,967
Fiscal 2020
Executive Total
Frank Laukien $4,081,963
Mark R. Munch $1,767,427
Gerald Herman $1,303,121
Juergen W. Srega $1,266,666
Falko Busse $871,812
Fiscal 2019
Executive Total
Frank Laukien $4,909,641
Mark R. Munch $1,697,249
Juergen W. Srega $1,327,857
Gerald Herman $1,248,193
Falko Busse $950,030
Fiscal 2018
Executive Total
Frank Laukien $4,479,899
Mark R. Munch $1,820,807
Bruker NANO Group $1,820,807
Juergen W. Srega $1,390,793
Gerald Herman $1,026,521
BioSpin Group $699,245
Falko Busse $699,245
Fiscal 2017
Executive Total
Frank Laukien $4,872,009
Mark R. Munch $1,851,936
CALID Group $1,355,291
Key facts CIK 1109354 CUSIP 116794108 13F (30d) 74 filings 74 filers Visit website Investor relations